Metabolism

Study of metabolic and endocrine diseases involves the genetic, biochemical, molecular, and cellular mechanisms in their development which may be used both in animal models and in human medicine. Inborn errors of metabolism and their early diagnosis and treatment are one of the key pillars in the clinical research. The intensive study is concentrated on the early stages of obesity, nutrition disorders, lipid metabolism and diabetes as well as on the research of adipose tissue and on its regulatory role. A development of widely occuring metabolic diseases supports the studies of the pathogenesis of complications with orientation to the vessel wall impairment and the markers of these changes. The interventions of the metabolic diseases involving the non-pharmacological (nutritional, regimen or surgical interventions) and pharmacological treatments are evaluated with the help of molecular biology and immunology and with the use of markers characterized the oxidative stress and subclinical inflammation. The discoveries have been used as the effective sources for the prevention. The endocrine disorders involve the diagnoses and treatment of the inflammatory and tumor processes of all endocrine organs including the research of their metabolic effects and their influence on gravidity.

Selected outputs

• Hodulova, M, Šedová, L, Křenová, D, Liška, F, Krupkova, M, Kazdova, L, Tremblay, J, Hamet, P, Křen, V, Šeda, O: Genomic Determinants of Triglyceride and Cholesterol Distribution into Lipoprotein Fractions in the Rat. PLOS ONE 9, 2014, Article Number: e109983

• Stránecký V, Hoischen A, Hartmannová H, Zaki MS, Chaudhary A, Zudaire E, Nosková L, Barešová V, Přistoupilová A, Hodaňová K, Sovová J, Hůlková H, Piherová L, Hehir-Kwa JY, de Silva D, Senanayake MP, Farrag S, Zeman J, Martásek P, Baxová A, Afifi HH, St Croix B, Brunner HG, Temtamy S, Kmoch S: Mutations in ANTXR1 cause GAPO syndrome. Am J Hun Genet 92, 2013, 792-799.

• Škrha J jr, Kalousová M, Švarcová J, Muravská A, Kvasnička J, Landová L, Zima T, Škrha J: Relationship of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in Type 1 and Type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 120, 2012, 277-281.

• Rossmeislová L, Malisová L, Kračmerová J, Tencerová M, Kovácová Z, Koc M, Šiklová-Vítková M, Viquerie N, Langin D, Štich V: Weight loss improves the adipogenic capacity of human preadipocytes and modulates their secretory profile. Diabetes 62, 2013, 1990-1995.